{"ticker": {"uuid": "c189606a-3de7-4ddb-94dc-2a347ff8a0cd", "symbol": "MBIO", "name": "Mustang Bio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Mustang Bio stock trades lower as cash runway and trial update shape outlook", "summary": "Mustang Bio's stock is trading lower due to a limited cash runway, ongoing clinical trials for rare cancers and gene therapy, and the search for strategic options. The company reported $0 revenue in Q1 2026 but narrowed its net loss to $7.8 million, with a cash balance of $24 mil", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mustang-bio-stock-trades-lower-as-cash-runway-and-trial-update-shape/69788775", "source_name": "Ad Hoc News", "published_at": "2026-07-17T18:38:00", "published_display": "17 Jul 2026 18:38", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mustang Bio (MBIO) Registration Filing Summary", "summary": "This article summarizes a Mustang Bio (MBIO) registration filing from November 29, 2025. It details the company's focus on cell and gene therapies, its significant accumulated deficit ($386.2 million as of March 31, 2024), and its ongoing efforts to raise capital through offering", "url": "https://quartr.com/events/mustang-bio-inc-mbio-registration-filing_FP0KdRGT", "source_name": "Quartr", "published_at": "2026-07-08T06:10:11", "published_display": "08 Jul 2026 06:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Proxy Filing Summary", "summary": "Mustang Bio (MBIO) has scheduled its Annual Meeting for December 22, 2025, to be held virtually, where stockholders will vote on key corporate matters. These include the election of seven directors, ratification of KPMG LLP as auditor, and amendments to the 2019 Employee Stock Pu", "url": "https://quartr.com/events/mustang-bio-inc-mbio-proxy-filing_FP0KdQ5T", "source_name": "Quartr", "published_at": "2026-07-07T20:41:59", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Q1 2026 earnings summary", "summary": "Mustang Bio (MBIO) reported a net loss of $0.96 million for Q1 2026, an increase from $0.15 million in Q1 2025, despite a decrease in operating expenses. The clinical-stage biopharma company, which has no approved products or revenue, continues to develop novel therapies for canc", "url": "https://quartr.com/events/mustang-bio-inc-mbio-q1-2026_FP0KdqgU", "source_name": "Quartr", "published_at": "2026-07-07T20:41:59", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (Nasdaq:MBIO) - Stock Analysis", "summary": "Mustang Bio, Inc. (Nasdaq:MBIO) is a clinical-stage biopharmaceutical company focused on cell therapies for cancers and autoimmune diseases, with a current market cap of US$5.3 million. The company faces significant financial risks including low market cap, lack of revenue, share", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbio/mustang-bio", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:10:41", "published_display": "02 Jul 2026 04:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Mustang Bio, Inc. (NASDAQ: MBIO). It indicates the period, value, and change associated with this financial ratio for the company, noting that the market is currently closed.", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:10:38", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "The article presents information regarding Mustang Bio, Inc. (NASDAQ:MBIO), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial data snippet or a page from a financial tracking platform like TradingView, providing metrics for the pharmaceut", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:39:50", "published_display": "30 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "This article references the enterprise value to EBITDA forward for Mustang Bio, Inc. (NASDAQ: MBIO). It lists the company on the Nasdaq Stock Market and provides general financial overview information. The content primarily consists of navigation links and stock market data discl", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:41:17", "published_display": "28 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mustang Bio, Inc. \u2013 BOATS:MBIO", "summary": "This article provides financial information for Mustang Bio, Inc. (MBIO) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the company's enterprise value to EBIT forward. The data presented is provided by ICE Data Services and FactSet Research Systems", "url": "https://www.tradingview.com/symbols/BOATS-MBIO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T19:11:51", "published_display": "28 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Mustang Bio, Inc. \u2013 BOATS:MBIO", "summary": "This article provides financial data, specifically the \"Price to earnings forward,\" for Mustang Bio, Inc. (BOATS:MBIO) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, offering a snapshot of a single financial metric without fu", "url": "https://www.tradingview.com/symbols/BOATS-MBIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:39:50", "published_display": "28 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "This article provides financial information for Mustang Bio, Inc. (NASDAQ: MBIO), specifically focusing on its price-to-earnings forward valuation. It appears to be a financial data page from TradingView, showing market information and a general overview for the company. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:34", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio, Inc. Actuals & Estimates (NASDAQ:MBIO)", "summary": "This article provides an overview of Mustang Bio, Inc. (NASDAQ:MBIO) stock, including its current price, historical performance, and financial estimates. It details market capitalization, volatility, upcoming earnings reports, and technical analysis, concluding with guidance on h", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T13:39:28", "published_display": "25 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBIO - A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???", "summary": "This article argues that Mustang Bio (MBIO) is significantly undervalued, trading below its cash and net asset value. The author highlights the clinical potential of MBIO's CAR-T therapy for glioblastoma, which has shown complete remission data, and the company's strategic pivot ", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-mbio/mustang-bio/rxhseadq-a-car-t-therapy-pipeline-with-complete-remission-cr-data-priced-as-a-negative-asset", "source_name": "Simply Wall Street", "published_at": "2026-06-24T14:11:51", "published_display": "24 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Ongoing Clinical-Stage Challenges - ROE Trend Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPY3EtM0FocTRkaXJ5cmk2VjFwRC1QOWtseDQ2WllwdXhyaGhUdEJXak1OdnU2enVtUUxZUi00aWk5YWhtWV9UMW96R01qeWpTakFIWl9nemVqWmZEV21fTmhTRTFHYVJfQXhTeXMyclcxdDh2Tld0WkVCeFpTb2xGWVhKWUoydHVBS1k4d0dzS1UybThDMEhSZVN5Z3hwZVlaa1oxclNST2d1U1pWMjZjdFZJc0liV01xbi1acS1CbHJGaVVmdVExMC0wZFRvdzZyZTJLUnAwWm1QYmhuYWc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Mustang Bio Inc (MBIO), highlighting its beta value of 2.08, indicating higher volatility compared to the S&P 500. While a formal risk assessment score is not yet available, the article details various metrics including VaR, maximum dra", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-22T01:41:17", "published_display": "22 Jun 2026 01:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Mustang Bio Inc (MBIO), noting that no earnings forecast score is currently available, which is below the Biotechnology & Medical Research industry average of 8.13. The report indicates that relevant financial forecasting data for EP", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-21T13:40:33", "published_display": "21 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Institutional Confidence", "summary": "This article from TradingKey focuses on the institutional confidence in Mustang Bio Inc (MBIO). It provides a table detailing significant institutional shareholders, the number of shares they hold, and the percentage change in their holdings. The institutional confidence score re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T22:10:12", "published_display": "18 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of Mustang Bio Inc's (MBIO) dividends and stock splits. It notes that the company has distributed $0.00 in dividends over the past five years. The document also lists several past and future stock mergers for MBIO, including a 50-to-1 m", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T21:40:39", "published_display": "18 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Mustang Bio Inc (MBIO) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:15", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Mustang Bio Inc (MBIO), focusing on its price momentum, support, resistance levels, and various technical indicators. It notes that MBIO's current price momentum score is 2.09, ranking low in its industry, and the stock is trading bet", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/technical", "source_name": "TradingKey", "published_at": "2026-06-16T20:42:13", "published_display": "16 Jun 2026 20:42", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "Mustang Bio Inc (MBIO) has a current valuation score of 8.09, placing it 171st out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.47, indicating it is significantly below its recent high and above its recent low. However, relevant data for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-15T08:40:44", "published_display": "15 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Mustang Bio Inc (MBIO) has a current financial score of 7.56, placing it 107th out of 388 in the Biotechnology & Medical Research industry. The company's financial status is considered robust, but its operating efficiency is low. Several key financial data points related to quali", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/financial-health", "source_name": "TradingKey", "published_at": "2026-06-15T08:40:44", "published_display": "15 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc. (MBIO) Q4 2024 Earnings: EPS Misses by Wide Margin Amid No Revenue; Stock Declines - Downward Estimate Revision", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPSWg4UTgxbnRZN0RoWFBLQVFnUkFHRkRCeGVmNzZiTUYybUtNbWk3RmtKZ0VOdmZTc016NVl3NVhmRkU2bWJULW1QNVZPOFhiQ293OW5QcEl6bkRZaFpfREdGWFRXOHlUOF91RnpkX3RIeVhoSmhuaHJ2YmNpMTUwWlZ1dTc1WHJtRFdWaEFiOXd6RHBsM3FrSUQ2cVEyX2xRUTdaNnpJU090NmMtcHd1R1JiUVhYdC03NkxzcVJKSEhFT0d6NDZHSnNDd3hiQQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 44, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Q4 2024 Earnings: Wider-Than-Expected Losses Offset by Positive Stock Movement Amid Pipeline Focus - Earnings Quality Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNb3dNempENE9BeUNBVEQtdnlGeTk0M01FTTRfWVE3VlZwNW10Z1NjX21wdW1pSF9SWmNqZzVxTEZ6dDA2b2s0a0lWT3BXREFNMllhT2IzN3NPM1BhQk1UX184NlNuakxNZ1RGNU00OEdwam8wQkVaRk83X01hcWJNbUZtWFVsRW93TFc1aWNvODVoenNWejlzLXItVTFIa3dzOTQ1YWRLekc5cW13aGRlclZzNUNUSzhfSXpGNG1LOTFrM2lfVXFXbmdXRU51R0RBMXA3MjRjOUZkaTVxZmoyZVJlR0ppMUtDbHJUSg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage - Post-Earnings Reaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZUdEM2VjUGtVdDc1elBNMGo2TW5wazNUUW0wdndVN3N4ZVRiT1g0QnZTSm8ydl80Q1M5WUpfSmQ2eG1nT1NnSC03MWF0S0xlT01aaG9rbnZ0Nlljak9QeHpUY0h5ME9jYjlPWnk1UVVIU3R6QmNocGROVDhhcFJzbFI2RjY1N0VhQ0J2c2VoTHM2aTZNNWFQVGI3d1lRM2E0UjU0a3BGSGI2U3MwUVdNeFNWOVU4WkZZTWtrUWZaeDQ1UQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio stock (US62815P1003): restructuring progress keeps spotlight on cash and pipeline", "summary": "Mustang Bio is actively restructuring, selling assets, and refocusing its resources on core cell and gene therapy programs to stabilize its financial position. The company aims to advance its pipeline through clinical development, relying on external financing, collaborations, an", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mustang-bio-stock-us62815p1003-restructuring-progress-keeps-spotlight/69358303", "source_name": "AD HOC NEWS", "published_at": "2026-05-17T16:40:51", "published_display": "17 May 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio stock (US62815P1003): restructuring moves and Nasdaq relisting plan put focus back on cell therapy pipeline", "summary": "Mustang Bio is repositioning itself through a reverse stock split and cost cuts to regain Nasdaq compliance and extend its cash runway. The company focuses on developing cell and gene therapies for cancer and rare diseases, emphasizing its CAR-T programs. While the restructuring ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mustang-bio-stock-us62815p1003-restructuring-moves-and-nasdaq-relisting/69349241", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T10:09:33", "published_display": "16 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mustang Bio Inc MBIO", "summary": "This page provides an overview of Mustang Bio Inc. (MBIO) stock, including its current price, market capitalization, and performance. It indicates a closing price of 0.660 USD, a decrease of 5.17%, and shows after-hours trading at 0.000 USD. The page offers various financial anal", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/comments", "source_name": "TradingKey", "published_at": "2026-05-12T02:10:04", "published_display": "12 May 2026 02:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mustang Bio (NASDAQ: MBIO) CEO reports 19-share tax withholding event", "summary": "Mustang Bio's President, CEO, and Interim CFO, Manuel Litchman, reported a routine tax-withholding transaction on April 24, 2026. He relinquished 19 shares of common stock at $0.75 per share to cover tax liability related to the vesting of restricted stock units. This was not an ", "url": "https://www.stocktitan.net/sec-filings/MBIO/form-4-mustang-bio-inc-insider-trading-activity-ccb0fa2644ce.html", "source_name": "Stock Titan", "published_at": "2026-04-27T19:38:40", "published_display": "27 Apr 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mustang Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Mustang Bio (MBIO) received a notice from Nasdaq on April 15, 2026, indicating non-compliance with the minimum $1.00 bid price rule for 30 consecutive business days. The company has until October 12, 2026, to regain compliance by achieving a closing bid price of at least $1.00 fo", "url": "https://www.tradingview.com/news/tradingview:ea4a0c71bb7c8:0-mustang-bio-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-04-18T01:09:10", "published_display": "18 Apr 2026 01:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Mustang Bio (MBIO) on sub-$1 share price and listing risk", "summary": "Mustang Bio Inc. (MBIO) has received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, as its stock traded below this level for 30 consecutive business days. The company now has a 180-day grace period, until October 12, 2026, to regain compliance b", "url": "https://www.stocktitan.net/sec-filings/MBIO/8-k-mustang-bio-inc-reports-material-event-25101853e9f9.html", "source_name": "Stock Titan", "published_at": "2026-04-17T19:39:00", "published_display": "17 Apr 2026 19:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-1 - General form for registration of securities under the Securities Act of 1933", "summary": "Mustang Bio, Inc. has filed a Form S-1 registration statement with the SEC to register the resale of up to 2,743,530 shares of its Common Stock by selling stockholders. These shares are issuable upon the exercise of warrants. The company will not receive any proceeds from these s", "url": "https://br.advfn.com/noticias/EDGAR2/2023/artigo/92785398", "source_name": "ADVFN", "published_at": "2026-04-17T07:40:22", "published_display": "17 Apr 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mustang Bio (MBIO) a Hidden Gem in the Microbiome Revolution, or a Risky Bet", "summary": "Mustang Bio (MBIO) is a clinical-stage biopharmaceutical company trading at a micro-cap valuation, focusing on cell and gene therapies for cancers and rare genetic diseases. While the broader biotech market is enthusiastic about microbiome-targeted interventions, MBIO's current p", "url": "https://www.kavout.com/market-lens/is-mustang-bio-mbio-a-hidden-gem-in-the-microbiome-revolution-or-a-risky-bet", "source_name": "Kavout", "published_at": "2026-04-12T05:10:04", "published_display": "12 Apr 2026 05:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mustang Bio\u2019s CAR-T MB-106 Achieves Responses in 9 of 10 Patients With Waldenstrom Macroglobulinemia", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNVlNwRXBuX0ZBdmFTemZBQzE1LTUzTzZJNDZ3V3BCV0xrdUZLUXg1S1dSYk95b19qT2oyMWl0NjNtY09XSmRaMHpOVDRhandLWlJVRTh4Rnd6b3o5alNVTnlSdXFXZllqZHA3a3VUOEItZTRMV3k2RFFHUFd4UDRoVlB6TlZaQl90SThnOXJ6emVKeFJ6WWlWczJxYUNENWtpM3RJY2VsWUx3R3RlQXpaZDVHcFNtUUk?oc=5", "source_name": "CGTLive\u00ae", "published_at": "2024-06-18T07:00:00+00:00", "published_display": "18 Jun 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Worcester biopharmaceutical firm Mustang Bio to lay off 81% of staff", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNVDk4Z2dOTDBWWVpOcGg3eElZYTdOa2xBWURHZW93X3hqNTUxMkNrWXJTakZpZVFQRkU5ZndTSV81TUp1Vnh4bUJVZ3lSRy1EcmNnLXBHNjZsQTBsLURVUWRTWDBjamN0X2pQaWhyUzdtaERockZiWk5ac25VSWhXN0pHeUZLejNKYjFPdnBaZjMtSTkxQ1BLdWRfek1pV2s?oc=5", "source_name": "Worcester Business Journal", "published_at": "2024-04-17T07:00:00+00:00", "published_display": "17 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Stock Price Forecast. Should You Buy MBIO?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTFBvNmt1djRaSnFIS0FkN0dCUVFITzk2TXpFSVk4T1ZCeXZoMnliSWR1T2NWZ2FsMF8ycFl4UU5JQnFpNlA4bW91cA?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T19:14:27+00:00", "published_display": "01 Dec 2020 19:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBhVDJLbThhZFZici1nRUFRSjBsMXdXZVNDMFRtNGFRbnB5S1RlR3pFYnpmLWZWY3BEcGo1dmJydk9yU2dFeTF2Qmdidm50THFDYW1SWi1wTFB2dw?oc=5", "source_name": "MarketBeat", "published_at": "2017-11-09T20:50:02+00:00", "published_display": "09 Nov 2017 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Mustang Bio (MBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE0zbjZ3dFc2UG1jUTBNOU5halpzQ24zZ3ZnT0t3VXgyNHJNcEhtRFVnajNSeDFkNGtYRjIzQm5jWWFKNE9ocnRvOTBuUjNHaFJDVksxanhfNDBOaTl0Z0hiSHByNlZhbkZKXzFXNg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2017-08-31T02:42:55+00:00", "published_display": "31 Aug 2017 02:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Mustang Bio stock trades lower as cash runway and trial update shape outlook", "summary": "Mustang Bio's stock is trading lower due to a limited cash runway, ongoing clinical trials for rare cancers and gene therapy, and the search for strategic options. The company reported $0 revenue in Q1 2026 but narrowed its net loss to $7.8 million, with a cash balance of $24 mil", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mustang-bio-stock-trades-lower-as-cash-runway-and-trial-update-shape/69788775", "source_name": "Ad Hoc News", "published_at": "2026-07-17T18:38:00", "published_display": "17 Jul 2026 18:38", "sentiment": "negative", "sentiment_pct": 36, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Registration Filing Summary", "summary": "This article summarizes a Mustang Bio (MBIO) registration filing from November 29, 2025. It details the company's focus on cell and gene therapies, its significant accumulated deficit ($386.2 million as of March 31, 2024), and its ongoing efforts to raise capital through offering", "url": "https://quartr.com/events/mustang-bio-inc-mbio-registration-filing_FP0KdRGT", "source_name": "Quartr", "published_at": "2026-07-08T06:10:11", "published_display": "08 Jul 2026 06:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Proxy Filing Summary", "summary": "Mustang Bio (MBIO) has scheduled its Annual Meeting for December 22, 2025, to be held virtually, where stockholders will vote on key corporate matters. These include the election of seven directors, ratification of KPMG LLP as auditor, and amendments to the 2019 Employee Stock Pu", "url": "https://quartr.com/events/mustang-bio-inc-mbio-proxy-filing_FP0KdQ5T", "source_name": "Quartr", "published_at": "2026-07-07T20:41:59", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Q1 2026 earnings summary", "summary": "Mustang Bio (MBIO) reported a net loss of $0.96 million for Q1 2026, an increase from $0.15 million in Q1 2025, despite a decrease in operating expenses. The clinical-stage biopharma company, which has no approved products or revenue, continues to develop novel therapies for canc", "url": "https://quartr.com/events/mustang-bio-inc-mbio-q1-2026_FP0KdqgU", "source_name": "Quartr", "published_at": "2026-07-07T20:41:59", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (Nasdaq:MBIO) - Stock Analysis", "summary": "Mustang Bio, Inc. (Nasdaq:MBIO) is a clinical-stage biopharmaceutical company focused on cell therapies for cancers and autoimmune diseases, with a current market cap of US$5.3 million. The company faces significant financial risks including low market cap, lack of revenue, share", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbio/mustang-bio", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:10:41", "published_display": "02 Jul 2026 04:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Mustang Bio, Inc. (NASDAQ: MBIO). It indicates the period, value, and change associated with this financial ratio for the company, noting that the market is currently closed.", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T05:10:38", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "The article presents information regarding Mustang Bio, Inc. (NASDAQ:MBIO), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial data snippet or a page from a financial tracking platform like TradingView, providing metrics for the pharmaceut", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T01:39:50", "published_display": "30 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "This article references the enterprise value to EBITDA forward for Mustang Bio, Inc. (NASDAQ: MBIO). It lists the company on the Nasdaq Stock Market and provides general financial overview information. The content primarily consists of navigation links and stock market data discl", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:41:17", "published_display": "28 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Mustang Bio, Inc. \u2013 BOATS:MBIO", "summary": "This article provides financial information for Mustang Bio, Inc. (MBIO) on the Blue Ocean Alternative Trade System (BOATS). It specifically highlights the company's enterprise value to EBIT forward. The data presented is provided by ICE Data Services and FactSet Research Systems", "url": "https://www.tradingview.com/symbols/BOATS-MBIO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T19:11:51", "published_display": "28 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Mustang Bio, Inc. \u2013 BOATS:MBIO", "summary": "This article provides financial data, specifically the \"Price to earnings forward,\" for Mustang Bio, Inc. (BOATS:MBIO) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, offering a snapshot of a single financial metric without fu", "url": "https://www.tradingview.com/symbols/BOATS-MBIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:39:50", "published_display": "28 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Mustang Bio, Inc. \u2013 NASDAQ:MBIO", "summary": "This article provides financial information for Mustang Bio, Inc. (NASDAQ: MBIO), specifically focusing on its price-to-earnings forward valuation. It appears to be a financial data page from TradingView, showing market information and a general overview for the company. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:34", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio, Inc. Actuals & Estimates (NASDAQ:MBIO)", "summary": "This article provides an overview of Mustang Bio, Inc. (NASDAQ:MBIO) stock, including its current price, historical performance, and financial estimates. It details market capitalization, volatility, upcoming earnings reports, and technical analysis, concluding with guidance on h", "url": "https://www.tradingview.com/symbols/NASDAQ-MBIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T13:39:28", "published_display": "25 Jun 2026 13:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MBIO - A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???", "summary": "This article argues that Mustang Bio (MBIO) is significantly undervalued, trading below its cash and net asset value. The author highlights the clinical potential of MBIO's CAR-T therapy for glioblastoma, which has shown complete remission data, and the company's strategic pivot ", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-mbio/mustang-bio/rxhseadq-a-car-t-therapy-pipeline-with-complete-remission-cr-data-priced-as-a-negative-asset", "source_name": "Simply Wall Street", "published_at": "2026-06-24T14:11:51", "published_display": "24 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Ongoing Clinical-Stage Challenges - ROE Trend Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxPY3EtM0FocTRkaXJ5cmk2VjFwRC1QOWtseDQ2WllwdXhyaGhUdEJXak1OdnU2enVtUUxZUi00aWk5YWhtWV9UMW96R01qeWpTakFIWl9nemVqWmZEV21fTmhTRTFHYVJfQXhTeXMyclcxdDh2Tld0WkVCeFpTb2xGWVhKWUoydHVBS1k4d0dzS1UybThDMEhSZVN5Z3hwZVlaa1oxclNST2d1U1pWMjZjdFZJc0liV01xbi1acS1CbHJGaVVmdVExMC0wZFRvdzZyZTJLUnAwWm1QYmhuYWc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Mustang Bio Inc (MBIO), highlighting its beta value of 2.08, indicating higher volatility compared to the S&P 500. While a formal risk assessment score is not yet available, the article details various metrics including VaR, maximum dra", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-22T01:41:17", "published_display": "22 Jun 2026 01:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Mustang Bio Inc (MBIO), noting that no earnings forecast score is currently available, which is below the Biotechnology & Medical Research industry average of 8.13. The report indicates that relevant financial forecasting data for EP", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-21T13:40:33", "published_display": "21 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Institutional Confidence", "summary": "This article from TradingKey focuses on the institutional confidence in Mustang Bio Inc (MBIO). It provides a table detailing significant institutional shareholders, the number of shares they hold, and the percentage change in their holdings. The institutional confidence score re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T22:10:12", "published_display": "18 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of Mustang Bio Inc's (MBIO) dividends and stock splits. It notes that the company has distributed $0.00 in dividends over the past five years. The document also lists several past and future stock mergers for MBIO, including a 50-to-1 m", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T21:40:39", "published_display": "18 Jun 2026 21:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Mustang Bio Inc (MBIO) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It primarily serves as a placeholder fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:15", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Mustang Bio Inc (MBIO), focusing on its price momentum, support, resistance levels, and various technical indicators. It notes that MBIO's current price momentum score is 2.09, ranking low in its industry, and the stock is trading bet", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/technical", "source_name": "TradingKey", "published_at": "2026-06-16T20:42:13", "published_display": "16 Jun 2026 20:42", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "Mustang Bio Inc (MBIO) has a current valuation score of 8.09, placing it 171st out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.47, indicating it is significantly below its recent high and above its recent low. However, relevant data for ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-15T08:40:44", "published_display": "15 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc (MBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Mustang Bio Inc (MBIO) has a current financial score of 7.56, placing it 107th out of 388 in the Biotechnology & Medical Research industry. The company's financial status is considered robust, but its operating efficiency is low. Several key financial data points related to quali", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/financial-health", "source_name": "TradingKey", "published_at": "2026-06-15T08:40:44", "published_display": "15 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc. (MBIO) Q4 2024 Earnings: EPS Misses by Wide Margin Amid No Revenue; Stock Declines - Downward Estimate Revision", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPSWg4UTgxbnRZN0RoWFBLQVFnUkFHRkRCeGVmNzZiTUYybUtNbWk3RmtKZ0VOdmZTc016NVl3NVhmRkU2bWJULW1QNVZPOFhiQ293OW5QcEl6bkRZaFpfREdGWFRXOHlUOF91RnpkX3RIeVhoSmhuaHJ2YmNpMTUwWlZ1dTc1WHJtRFdWaEFiOXd6RHBsM3FrSUQ2cVEyX2xRUTdaNnpJU090NmMtcHd1R1JiUVhYdC03NkxzcVJKSEhFT0d6NDZHSnNDd3hiQQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 44, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Q4 2024 Earnings: Wider-Than-Expected Losses Offset by Positive Stock Movement Amid Pipeline Focus - Earnings Quality Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNb3dNempENE9BeUNBVEQtdnlGeTk0M01FTTRfWVE3VlZwNW10Z1NjX21wdW1pSF9SWmNqZzVxTEZ6dDA2b2s0a0lWT3BXREFNMllhT2IzN3NPM1BhQk1UX184NlNuakxNZ1RGNU00OEdwam8wQkVaRk83X01hcWJNbUZtWFVsRW93TFc1aWNvODVoenNWejlzLXItVTFIa3dzOTQ1YWRLekc5cW13aGRlclZzNUNUSzhfSXpGNG1LOTFrM2lfVXFXbmdXRU51R0RBMXA3MjRjOUZkaTVxZmoyZVJlR0ppMUtDbHJUSg?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Stage - Post-Earnings Reaction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZUdEM2VjUGtVdDc1elBNMGo2TW5wazNUUW0wdndVN3N4ZVRiT1g0QnZTSm8ydl80Q1M5WUpfSmQ2eG1nT1NnSC03MWF0S0xlT01aaG9rbnZ0Nlljak9QeHpUY0h5ME9jYjlPWnk1UVVIU3R6QmNocGROVDhhcFJzbFI2RjY1N0VhQ0J2c2VoTHM2aTZNNWFQVGI3d1lRM2E0UjU0a3BGSGI2U3MwUVdNeFNWOVU4WkZZTWtrUWZaeDQ1UQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio stock (US62815P1003): restructuring progress keeps spotlight on cash and pipeline", "summary": "Mustang Bio is actively restructuring, selling assets, and refocusing its resources on core cell and gene therapy programs to stabilize its financial position. The company aims to advance its pipeline through clinical development, relying on external financing, collaborations, an", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mustang-bio-stock-us62815p1003-restructuring-progress-keeps-spotlight/69358303", "source_name": "AD HOC NEWS", "published_at": "2026-05-17T16:40:51", "published_display": "17 May 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio stock (US62815P1003): restructuring moves and Nasdaq relisting plan put focus back on cell therapy pipeline", "summary": "Mustang Bio is repositioning itself through a reverse stock split and cost cuts to regain Nasdaq compliance and extend its cash runway. The company focuses on developing cell and gene therapies for cancer and rare diseases, emphasizing its CAR-T programs. While the restructuring ", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mustang-bio-stock-us62815p1003-restructuring-moves-and-nasdaq-relisting/69349241", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T10:09:33", "published_display": "16 May 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Inc MBIO", "summary": "This page provides an overview of Mustang Bio Inc. (MBIO) stock, including its current price, market capitalization, and performance. It indicates a closing price of 0.660 USD, a decrease of 5.17%, and shows after-hours trading at 0.000 USD. The page offers various financial anal", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mbio/comments", "source_name": "TradingKey", "published_at": "2026-05-12T02:10:04", "published_display": "12 May 2026 02:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (NASDAQ: MBIO) CEO reports 19-share tax withholding event", "summary": "Mustang Bio's President, CEO, and Interim CFO, Manuel Litchman, reported a routine tax-withholding transaction on April 24, 2026. He relinquished 19 shares of common stock at $0.75 per share to cover tax liability related to the vesting of restricted stock units. This was not an ", "url": "https://www.stocktitan.net/sec-filings/MBIO/form-4-mustang-bio-inc-insider-trading-activity-ccb0fa2644ce.html", "source_name": "Stock Titan", "published_at": "2026-04-27T19:38:40", "published_display": "27 Apr 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Mustang Bio (MBIO) received a notice from Nasdaq on April 15, 2026, indicating non-compliance with the minimum $1.00 bid price rule for 30 consecutive business days. The company has until October 12, 2026, to regain compliance by achieving a closing bid price of at least $1.00 fo", "url": "https://www.tradingview.com/news/tradingview:ea4a0c71bb7c8:0-mustang-bio-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-04-18T01:09:10", "published_display": "18 Apr 2026 01:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Mustang Bio (MBIO) on sub-$1 share price and listing risk", "summary": "Mustang Bio Inc. (MBIO) has received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, as its stock traded below this level for 30 consecutive business days. The company now has a 180-day grace period, until October 12, 2026, to regain compliance b", "url": "https://www.stocktitan.net/sec-filings/MBIO/8-k-mustang-bio-inc-reports-material-event-25101853e9f9.html", "source_name": "Stock Titan", "published_at": "2026-04-17T19:39:00", "published_display": "17 Apr 2026 19:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form S-1 - General form for registration of securities under the Securities Act of 1933", "summary": "Mustang Bio, Inc. has filed a Form S-1 registration statement with the SEC to register the resale of up to 2,743,530 shares of its Common Stock by selling stockholders. These shares are issuable upon the exercise of warrants. The company will not receive any proceeds from these s", "url": "https://br.advfn.com/noticias/EDGAR2/2023/artigo/92785398", "source_name": "ADVFN", "published_at": "2026-04-17T07:40:22", "published_display": "17 Apr 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mustang Bio (MBIO) a Hidden Gem in the Microbiome Revolution, or a Risky Bet", "summary": "Mustang Bio (MBIO) is a clinical-stage biopharmaceutical company trading at a micro-cap valuation, focusing on cell and gene therapies for cancers and rare genetic diseases. While the broader biotech market is enthusiastic about microbiome-targeted interventions, MBIO's current p", "url": "https://www.kavout.com/market-lens/is-mustang-bio-mbio-a-hidden-gem-in-the-microbiome-revolution-or-a-risky-bet", "source_name": "Kavout", "published_at": "2026-04-12T05:10:04", "published_display": "12 Apr 2026 05:10", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio\u2019s CAR-T MB-106 Achieves Responses in 9 of 10 Patients With Waldenstrom Macroglobulinemia", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNVlNwRXBuX0ZBdmFTemZBQzE1LTUzTzZJNDZ3V3BCV0xrdUZLUXg1S1dSYk95b19qT2oyMWl0NjNtY09XSmRaMHpOVDRhandLWlJVRTh4Rnd6b3o5alNVTnlSdXFXZllqZHA3a3VUOEItZTRMV3k2RFFHUFd4UDRoVlB6TlZaQl90SThnOXJ6emVKeFJ6WWlWczJxYUNENWtpM3RJY2VsWUx3R3RlQXpaZDVHcFNtUUk?oc=5", "source_name": "CGTLive\u00ae", "published_at": "2024-06-18T07:00:00+00:00", "published_display": "18 Jun 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Worcester biopharmaceutical firm Mustang Bio to lay off 81% of staff", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNVDk4Z2dOTDBWWVpOcGg3eElZYTdOa2xBWURHZW93X3hqNTUxMkNrWXJTakZpZVFQRkU5ZndTSV81TUp1Vnh4bUJVZ3lSRy1EcmNnLXBHNjZsQTBsLURVUWRTWDBjamN0X2pQaWhyUzdtaERockZiWk5ac25VSWhXN0pHeUZLejNKYjFPdnBaZjMtSTkxQ1BLdWRfek1pV2s?oc=5", "source_name": "Worcester Business Journal", "published_at": "2024-04-17T07:00:00+00:00", "published_display": "17 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio Stock Price Forecast. Should You Buy MBIO?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTFBvNmt1djRaSnFIS0FkN0dCUVFITzk2TXpFSVk4T1ZCeXZoMnliSWR1T2NWZ2FsMF8ycFl4UU5JQnFpNlA4bW91cA?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-01T19:14:27+00:00", "published_display": "01 Dec 2020 19:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mustang Bio (MBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBhVDJLbThhZFZici1nRUFRSjBsMXdXZVNDMFRtNGFRbnB5S1RlR3pFYnpmLWZWY3BEcGo1dmJydk9yU2dFeTF2Qmdidm50THFDYW1SWi1wTFB2dw?oc=5", "source_name": "MarketBeat", "published_at": "2017-11-09T20:50:02+00:00", "published_display": "09 Nov 2017 20:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Mustang Bio (MBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE0zbjZ3dFc2UG1jUTBNOU5halpzQ24zZ3ZnT0t3VXgyNHJNcEhtRFVnajNSeDFkNGtYRjIzQm5jWWFKNE9ocnRvOTBuUjNHaFJDVksxanhfNDBOaTl0Z0hiSHByNlZhbkZKXzFXNg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2017-08-31T02:42:55+00:00", "published_display": "31 Aug 2017 02:42", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 47, "sentiment_summary": {"positive": 4, "negative": 17, "neutral": 26, "score": 44, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 11.9, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 17}, "market_context": {"has_market_context": true, "latest_close": 0.63, "latest_week": "2026-07-17", "one_week_move": -10.7, "four_week_move": -3.4, "twelve_week_move": -16.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.327417, "market_dynamics_buy_signal": false, "relative_strength": -49.500541, "fair_value_gap": -97.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 35.5663, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.7% over one week, -3.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 9}, {"label": "TradingKey", "count": 9}, {"label": "Market source", "count": 6}, {"label": "dars.gov.et", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "AD HOC NEWS", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 21}, {"label": "Market update", "count": 21}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "44/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.7% over one week, -3.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Mustang Bio stock trades lower as cash runway and trial update shape outlook"}], "updated_at": "2026-07-23T10:27:06.018387+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}